IndustryCompany release

Royalty Pharma raises 2026 Portfolio Receipts guidance to $3.50-3.55bn after 9% Q3 growth

🇺🇸 Royalty Pharma plc (RPRX) · Wed 04 Nov 2026

The royalty investor reported third-quarter Portfolio Receipts of $890m, lifted its full-year outlook and bought royalties on two newly commercial dermatology and rare-disease products for $100m each.

Royalty Pharma plc reported third-quarter 2026 results on 4 November, with Portfolio Receipts up 9% to $890m. Royalty Receipts, the main component, also rose 9%, to $883m.

The company named Tremfya, Voranigo, Evrysdi and Imdelltra as the drivers of growth in the quarter.

Following the performance, Royalty Pharma raised its full-year 2026 Portfolio Receipts guidance to $3,500-3,550m, from the previous range of $3,400-3,500m.

Royalty Pharma also reported two acquisitions, buying royalties on Arcutis's Zoryve and on Takeda's Mimrylo, at $100m each. It cited FDA approvals and positive Phase 3 data across its portfolio as part of the quarter's developments. The summary available does not give further detail on those regulatory events or the terms of the royalty deals.

What it means for your team

  • Growth in royalty receipts tied to Tremfya, Voranigo, Evrysdi and Imdelltra points to continued commercial uptake of these products, which market-access teams may want to factor into competitor and payer-landscape monitoring.
  • Royalty financiers are continuing to buy into recently launched or newly approved products such as Zoryve and Mimrylo, a sign of investor interest in their commercial prospects.
  • Regulatory teams tracking the portfolio should note that the company links its results to FDA approvals and positive Phase 3 readouts, although the specific products were not detailed in the material reviewed.

Company's press release (SEC filing): Royalty Pharma plc ↗

Article written by VigiEye from the official source (Royalty Pharma plc). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →